Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TAK 888

Drug Profile

TAK 888

Alternative Names: anti-SARS-CoV-2 polyclonal H-IG - Takeda; Anti-SARS-CoV-2 polyclonal hyperimmune globulin - Takeda; TAK-888

Latest Information Update: 13 Apr 2020

At a glance

  • Originator Takeda
  • Class Antivirals; Immunoglobulins; Polyclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - COVID 2019 infections

Highest Development Phases

  • Research COVID 2019 infections

Most Recent Events

  • 07 Apr 2020 Takeda collaborates with Biotest, Bio Products Laboratory (BPL), LFB, Octapharma and CSL Behring to develop an anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin therapeutic for COVID-2019
  • 04 Mar 2020 TAK 888 is available for licensing in Asia, Europe, USA as of 04 Mar 2020. https://www.takeda.com/
  • 04 Mar 2020 Early research in COVID-2019 infections in Japan (Parenteral) before March 2019

Development Overview

Introduction

TAK 888 is an anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG) being developed by Takeda for the treatment of COVID-2019 infections. Hyperimmune globulins are plasma derived-therapies. H-IG will act by concentrating the pathogen-specific antibodies from the plasma obtained from recovered patients or vaccinated donors in the future. Transferring the antibodies to a new patient can help that person’s immune system respond to the infection. Early research is underway in Japan.

As of March 2019, Takeda is in discussions with multiple national health and regulatory agencies and health care partners in the US, Asia, and Europe for the development of TAK 888 [1] .

Company Agreements

In April 2020, Biotest, Bio Products Laboratory (BPL), LFB, and Octapharma joined an alliance formed by CSL Behring and Takeda Pharmaceutical to develop a potential plasma-derived therapy for the treatment of COVID-19. The collaboration leads to the development of an unbranded anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin medicine with the potential to treat individuals with serious complications from COVID-19. The collaboration will leverage leading-edge expertise and work that the companies already have underway. Experts from the alliance will begin collaborating across key aspects such as plasma collections, clinical trial development and manufacturing. [2]

Key Development Milestones

As of March 2020, early research is underway for TAK 888 in Japan [1] .

Drug Properties & Chemical Synopsis

  • Route of administration Parenteral
  • Formulation unspecified
  • Class Antivirals, Immunoglobulins, Polyclonal antibodies
  • Mechanism of Action Immunomodulators
  • WHO ATC code

    J06B-C (Other immunoglobulins)

  • EPhMRA code

    J6H (Specific Immunoglobulins - Antiviral)

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
COVID 2019 infections - - Research Japan Parenteral / unspecified Takeda 04 Mar 2020

Commercial Information

Involved Organisations

Organisation Involvement Countries
Takeda Originator Japan
Takeda Owner Japan
Octapharma Collaborator Switzerland
LFB Collaborator France
Biotest AG Collaborator Germany
CSL Behring Collaborator USA
Bio Products Laboratory Collaborator United-Kingdom

Licensing Availability

Licensing Organisation Available Indication Available Phase Region Date
Takeda COVID 2019 infections Research Asia, Europe, USA 04 Mar 2020

Development History

Event Date Update Type Comment
07 Apr 2020 Licensing Status Takeda collaborates with Biotest, Bio Products Laboratory (BPL), LFB, Octapharma and CSL Behring to develop an anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin therapeutic for COVID-2019 [2] Updated 13 Apr 2020
04 Mar 2020 Licensing Status TAK 888 is available for licensing in Asia, Europe, USA as of 04 Mar 2020. https://www.takeda.com/ Updated 19 Mar 2020
04 Mar 2020 Phase Change Early research in COVID-2019 infections in Japan (Parenteral) before March 2019 [1] Updated 19 Mar 2020

References

  1. Takeda Initiates Development of a Plasma-Derived Therapy for COVID-19.

    Media Release
  2. Global Plasma Leaders Collaborate to Accelerate Development of Potential COVID-19 Hyperimmune Therapy.

    Media Release
Back to top